argenx just committed up to $1.15bn to a biotech with no disclosed clinical drug. What is it really buying?
argenx will pay $550 million upfront to acquire Unnatural Products in a deal worth up to $1.15 billion, adding oral peptide discovery.
Pharma & Biotech
Pharma & Biotech
argenx Forte Biosciences acquisition: What the $2.2bn FB102 deal means for immunology
argenx is buying Forte Biosciences for $2.2bn to secure FB102. See why early vitiligo and celiac data make Phase 2 execution decisive.